Tanaka Y - Search Results

1

Onishi M, Ochiya T, Tanaka Y. Onishi M, et al. Among authors: tanaka y. Cancer Drug Resist. 2020 Apr 17;3(3):385-400. doi: 10.20517/cdr.2019.110. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582451 Free PMC article. Review.

2

Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection.

Nakagawa S, Hirata Y, Kameyama T, Tokunaga Y, Nishito Y, Hirabayashi K, Yano J, Ochiya T, Tateno C, Tanaka Y, Mizokami M, Tsukiyama-Kohara K, Inoue K, Yoshiba M, Takaoka A, Kohara M. Nakagawa S, et al. Among authors: tanaka y. PLoS One. 2013;8(3):e59611. doi: 10.1371/journal.pone.0059611. Epub 2013 Mar 28. PLoS One. 2013. PMID: 23555725 Free PMC article.

3

microRNAs and Hepatitis B.

Naito Y, Tanaka Y, Ochiya T. Naito Y, et al. Among authors: tanaka y. Adv Exp Med Biol. 2015;888:389-99. doi: 10.1007/978-3-319-22671-2_19. Adv Exp Med Biol. 2015. PMID: 26663193

4

Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma.

Nojima M, Matsui T, Tamori A, Kubo S, Shirabe K, Kimura K, Shimada M, Utsunomiya T, Kondo Y, Iio E, Naito Y, Ochiya T, Tanaka Y. Nojima M, et al. Among authors: tanaka y. Mol Cancer. 2016 Apr 30;15(1):31. doi: 10.1186/s12943-016-0514-6. Mol Cancer. 2016. PMID: 27137948 Free PMC article.

5

Identification of the novel 3' UTR sequences of human IL-21 mRNA as potential targets of miRNAs.

Enomoto Y, Takagi R, Naito Y, Kiniwa T, Tanaka Y, Hamada-Tsutsumi S, Kawano M, Matsushita S, Ochiya T, Miyajima A. Enomoto Y, et al. Among authors: tanaka y. Sci Rep. 2017 Aug 10;7(1):7780. doi: 10.1038/s41598-017-07853-x. Sci Rep. 2017. PMID: 28798470 Free PMC article.

6

Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells.

Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T. Gailhouste L, et al. Among authors: tanaka y. Mol Ther. 2018 Jul 5;26(7):1840-1854. doi: 10.1016/j.ymthe.2018.04.018. Epub 2018 Apr 26. Mol Ther. 2018. PMID: 29759938 Free PMC article.

7

Screening of microRNAs for a repressor of hepatitis B virus replication.

Naito Y, Hamada-Tsutsumi S, Yamamoto Y, Kogure A, Yoshioka Y, Watashi K, Ochiya T, Tanaka Y. Naito Y, et al. Among authors: tanaka y. Oncotarget. 2018 Jul 6;9(52):29857-29868. doi: 10.18632/oncotarget.25557. eCollection 2018 Jul 6. Oncotarget. 2018. PMID: 30042818 Free PMC article.

8

The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection.

Hamada-Tsutsumi S, Naito Y, Sato S, Takaoka A, Kawashima K, Isogawa M, Ochiya T, Tanaka Y. Hamada-Tsutsumi S, et al. Among authors: tanaka y. Aliment Pharmacol Ther. 2019 Apr;49(8):1060-1070. doi: 10.1111/apt.15197. Epub 2019 Mar 3. Aliment Pharmacol Ther. 2019. PMID: 30828831

9

MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells.

Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Kato T, Nakagama H, Ochiya T. Gailhouste L, et al. Among authors: tanaka y. Cell Death Dis. 2019 Jul 18;10(8):553. doi: 10.1038/s41419-019-1788-6. Cell Death Dis. 2019. PMID: 31320614 Free PMC article.

10

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.

Naiki-Ito A, Naiki T, Kato H, Iida K, Etani T, Nagayasu Y, Suzuki S, Yamashita Y, Inaguma S, Onishi M, Tanaka Y, Yasui T, Takahashi S. Naiki-Ito A, et al. Among authors: tanaka y. Carcinogenesis. 2020 Aug 12;41(8):1145-1157. doi: 10.1093/carcin/bgz193. Carcinogenesis. 2020. PMID: 31805186 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,952 results

Search Page